Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib study
单位：[1]First Hosp Jilin Univ, Phase Clin Res Ctr 1, Changchun, Peoples R China[2]Guangdong Raynovent Biotech Co Ltd, Guangzhou, Peoples R China[3]Nanfang Med Univ, Nanfang Hosp, Guangzhou, Peoples R China[4]Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China首都医科大学附属北京友谊医院[5]First Hosp Jilin Univ, Radiol, Changchun, Peoples R China[6]First Hosp Jilin Univ, Hepatol, Changchun, Peoples R China
第一作者单位：[1]First Hosp Jilin Univ, Phase Clin Res Ctr 1, Changchun, Peoples R China
推荐引用方式(GB/T 7714)：
Hu Yue,Li Hai Jun,Zhang Hong,et al.Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib study[J].JOURNAL OF HEPATOLOGY.2022,77:S89-S89.
APA：
Hu, Yue,Li, Hai Jun,Zhang, Hong,Chen, Jinjun,Xu, Zhongyuan...&Ding, Yanhua.(2022).Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib study.JOURNAL OF HEPATOLOGY,77,
MLA：
Hu, Yue,et al."Safety, pharmacokinetics and efficacy of the novel pan-phosphodiesterase inhibitor ZSP1601 in 36 NASH patients: a double-blinded, placebo-controlled, multiple-dose escalation phase Ib study".JOURNAL OF HEPATOLOGY 77.(2022):S89-S89
医学